Granite Point Capital Management’s Capricor Therapeutics CAPR Stock Holding History

Granite Point Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,375	Closed	-$53K	–	111
2017 Q4	$53K	Hold	3,375	–	–	0.01%	98
2017 Q3	$102K	Hold	3,375	–	–	0.02%	98
2017 Q2	$28K	Sell	3,375 -2,430	-42%	-$44.5K	0.01%	100
2017 Q1	$193K	Sell	5,805 -945	-14%	-$26.2K	0.06%	82
2016 Q4	$180K	Hold	6,750	–	–	0.14%	78
2016 Q3	$219K	Buy	+6,750	New	+$254K	0.09%	85

Other funds holding CAPR

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Granite Point Capital Management's CAPR Position: Q1 2018 in Review

Granite Point Capital Management sold out of Capricor Therapeutics (CAPR) in Q1 2018, closing a stake of 3,375 shares — an estimated $53K sold.

Granite Point Capital Management first reported a position in CAPR in Q3 2016 and held it in 6 quarters. The position peaked at $219K in Q3 2016. 20 funds tracked by Wall St. Rank hold CAPR as of Q1 2018.

Granite Point Capital Management reported no remaining Capricor Therapeutics position as of Q1 2018 after selling out during the quarter.
Granite Point Capital Management sold 3,375 Capricor Therapeutics shares in Q1 2018, an estimated $53K.
Granite Point Capital Management first reported a position in Capricor Therapeutics in Q3 2016 and held it in 6 quarters.
Granite Point Capital Management's Capricor Therapeutics position peaked at $219K in Q3 2016.
20 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2018.

Based on Granite Point Capital Management's 13F filing for Q1 2018, filed 15 May 2018.